Allakos (NASDAQ:ALLK) Shares Gap Down to $7.43

Allakos Inc. (NASDAQ:ALLK – Get Rating) shares gapped down before the market opened on Wednesday . The stock had previously closed at $7.43, but opened at $7.26. Allakos shares last traded at $7.36, with a volume of 1,101 shares traded.

Allakos Stock Up 3.6 %

The company has a market capitalization of $657.77 million, a P/E ratio of -1.14 and a beta of 0.51. The company’s fifty day moving average price is $7.49 and its 200 day moving average price is $5.63.

Allakos (NASDAQ:ALLK – Get Rating) last posted its quarterly earnings results on Monday, November 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.25. Research analysts predict that Allakos Inc. will post -5.18 earnings per share for the current fiscal year.

Institutional Trading of Allakos

Several large investors have recently made changes to their positions in the company. Amalgamated Bank acquired a new stake in Allakos in the first quarter valued at approximately $33,000. Sei Investments Co. acquired a new stake in Allakos in the second quarter valued at approximately $46,000. Bayesian Capital Management LP acquired a new stake in Allakos in the third quarter valued at approximately $97,000. Quantbot Technologies LP acquired a new stake in Allakos in the first quarter valued at approximately $96,000. Finally, Ensign Peak Advisors Inc lifted its holdings in shares of Allakos by 163.6% during the first quarter. Ensign Peak Advisors Inc now owns 17,080 shares of the company’s stock worth $97,000 after purchasing an additional 10,600 shares during the period. Institutional investors and hedge funds own 93.07% of the company’s stock.

Allakos Company Profile

(Get Rating)

Allakos Inc, a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria.